X4 PHARMACEUTICALS, INC (XFOR)

4.04 -4.49% (-0.19)

Over 1Y: -1.9%

2026-08-28
3 4
Aug Oct Dec Feb Apr Jun Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '21 — Revenue: 0 Q3 '21 — Operating Cash Flow: -14.2M Q3 '21 — Free Cash Flow: -14.2M Q3 '21 — Net Income: -20.2M Q4 '21 — Revenue: 0 Q4 '21 — Operating Cash Flow: -19.1M Q4 '21 — Free Cash Flow: -19.1M Q4 '21 — Net Income: -30.2M Q1 '22 — Operating Cash Flow: -20.2M Q1 '22 — Free Cash Flow: -20.3M Q1 '22 — Net Income: -22M Q2 '22 — Operating Cash Flow: -18.5M Q2 '22 — Free Cash Flow: -18.5M Q2 '22 — Net Income: -21.2M Q3 '22 — Operating Cash Flow: -19.3M Q3 '22 — Free Cash Flow: -19.3M Q3 '22 — Net Income: -21.6M Q4 '22 — Operating Cash Flow: -19.1M Q4 '22 — Free Cash Flow: -19.1M Q4 '22 — Net Income: -29.1M Q1 '23 — Revenue: 0 Q1 '23 — Operating Cash Flow: -26.5M Q1 '23 — Free Cash Flow: -26.5M Q1 '23 — Net Income: -24M Q2 '23 — Revenue: 0 Q2 '23 — Operating Cash Flow: -47.9M Q2 '23 — Free Cash Flow: -47.9M Q2 '23 — Net Income: -55.7M Q3 '23 — Revenue: 0 Q3 '23 — Operating Cash Flow: -68.8M Q3 '23 — Free Cash Flow: -68.8M Q3 '23 — Net Income: -2.3M Q4 '23 — Revenue: 0 Q4 '23 — Operating Cash Flow: -27.7M Q4 '23 — Free Cash Flow: -27.8M Q4 '23 — Net Income: -19.1M Q1 '24 — Revenue: 0 Q1 '24 — Operating Cash Flow: -33.6M Q1 '24 — Free Cash Flow: -33.7M Q1 '24 — Net Income: -51.8M Q2 '24 — Revenue: 563K Q2 '24 — Operating Cash Flow: -63.9M Q2 '24 — Free Cash Flow: -64M Q2 '24 — Net Income: 90.8M Q3 '24 — Revenue: 560K Q3 '24 — Operating Cash Flow: -34M Q3 '24 — Free Cash Flow: -34.1M Q3 '24 — Net Income: -36.7M Q4 '24 — Revenue: 1.4M Q4 '24 — Operating Cash Flow: -33M Q4 '24 — Free Cash Flow: -33M Q4 '24 — Net Income: -39.8M Q1 '25 — Revenue: 28.8M Q1 '25 — Operating Cash Flow: -12.4M Q1 '25 — Free Cash Flow: -12.4M Q1 '25 — Net Income: 282K Q2 '25 — Revenue: 2M Q2 '25 — Operating Cash Flow: -29.9M Q2 '25 — Free Cash Flow: -29.9M Q2 '25 — Net Income: -25.7M Q3 '25 — Revenue: 1.8M Q3 '25 — Operating Cash Flow: -27.8M Q3 '25 — Free Cash Flow: -27.8M Q3 '25 — Net Income: -29.8M Q4 '25 — Revenue: 2.6M Q4 '25 — Operating Cash Flow: -15.5M Q4 '25 — Free Cash Flow: -15.5M Q4 '25 — Net Income: -23.9M Q1 '26 — Revenue: 2.7M Q1 '26 — Operating Cash Flow: -19.6M Q1 '26 — Net Income: -20.2M Q2 '26 — Revenue: 8.8M Q2 '26 — Operating Cash Flow: -20.8M Q2 '26 — Net Income: -16.2M -35M 0 35M 70M 105M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 53.8%
OE margin -582.2%
Oper. margin -554.7%
ROIC -196.4%
Accruals -2.5%
Gross margin 81.5%
Asset turnover 0.063×
EBITDA margin -544.2%
FCF margin -528.4%
OCF margin -528.4%
Profit margin -568.8%
ROA -35.6%
ROCE -37.6%
ROE -58.0%
Capex / sales —
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.7
RPO / sales 0.053×
RPO growth —
Segment HHI —

2 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.5
Current ratio 11.8×
ND/EBITDA —
Interest cover -10.1×
Cash / Debt 2.6×
Debt payback 0.0 yr
Quick ratio 11.2×
Cash runway 1.4 yr
Debt / Eq 0.48×
F-score 4.0 pts
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.4
Sales/sh Y/Y -92.3%
Sales Q/Q +346.3%
Shares change +531.8%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.